US5478859A - Indole-derivatives, method of treatment therewith, and pharmaceutical compositions comprising such compounds - Google Patents
Indole-derivatives, method of treatment therewith, and pharmaceutical compositions comprising such compounds Download PDFInfo
- Publication number
- US5478859A US5478859A US08/259,016 US25901694A US5478859A US 5478859 A US5478859 A US 5478859A US 25901694 A US25901694 A US 25901694A US 5478859 A US5478859 A US 5478859A
- Authority
- US
- United States
- Prior art keywords
- compound
- compounds
- disease
- hydrogen
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
Definitions
- the present invention relates to novel excitatory amino acid antagonists, including glutamate antagonists, a method of treatment therewith, pharmaceutical compositions comprising the compounds and to a method of preparing the novel compounds of the invention.
- Another object of the present invention is to provide a method of treating disorders or diseases of a living animal body, including a human, responsive to the antagonization of glutamate and aspartate which comprises administering to a living animal body, including a human, in need thereof a compound of the invention.
- a third object of the present invention is to provide novel pharmaceutical compositions for the treatment of disorders or diseases of a living animal body, including a human, responsive to the antagonization of glutamate and aspartate.
- EAA excitatory amino acids
- NMDA N-methyl-D-aspartate
- AMPA alfa-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
- This excitotoxic action is responsible for the loss of neurons in cerebrovascular disorders such as cerebral ischemia or cerebral infarction resulting from a range of conditions, such as thromboembolic or haemorrhagic stroke, cerebral vasospasm, hypoglycaemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery and cerebral trauma as well as lathyrism, Alzheimer's, and Huntington's diseases.
- cerebrovascular disorders such as cerebral ischemia or cerebral infarction resulting from a range of conditions, such as thromboembolic or haemorrhagic stroke, cerebral vasospasm, hypoglycaemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery and cerebral trauma as well as lathyrism, Alzheimer's, and Huntington's diseases.
- the compounds of the present invention may also be useful in the treatment of schizophrenia, Parkinsonism, epilepsy, anxiety, pain and drug addiction.
- the invention then, inter alia, comprises the following, alone or in combination:
- R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 13 , and R 14 each independently are hydrogen, halogen, CF 3 , CN, or NO 2 ;
- R 21 and R 22 are each methyl, R 2 , R 4 , R 12 , and R 14 are each NO 2 , and R 1 , R 3 , R 11 and R 13 are each hydrogen;
- a method of treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the antagonization of an excitatory amino acid, including glutamate and/or aspartate which comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound as any above;
- Alzheimer's disease Huntington's diseases, schizophrenia, Parkinsonism, epilepsy, anxiety, pain, drug addiction or the degenerative diseases or disorders following cerebral ischemia or cerebral infarction is treated;
- composition comprising a therapeutically-effective amount of a compound as any above together with at least one pharmaceutically-acceptable carrier;
- Examples of pharmaceutically-acceptable addition salts include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate, oxalate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, salicylate and the acetate.
- Such salts are formed by procedures well known in the art.
- Halogen is fluorine, chlorine, bromine, or iodine; chlorine and bromine are preferred groups.
- Alkyl means a straight chained or branched chain of from one to six carbon atoms or cyclic alkyl of from three to seven carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; methyl, ethyl, propyl and isopropyl are preferred groups.
- the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
- pharmaceutically acceptable solvents such as water, ethanol and the like.
- the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
- Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof, with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example.
- the compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the present invention with an optically active chloroformate or the like.
- an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid
- the compounds of the invention exhibit valuable biological properties because of their strong excitatory amino acid (EAA), including glutamate and/or aspartate antagonizing properties.
- EAA excitatory amino acid
- ATPA The selective glutamate receptor agonist at the AMPA(quisqualate)/glutamate receptor, ATPA, induce rigidity in female NMRI mice at doses between 3 and 15 mg/kg and clonic-tonic seizures and death, probably due to respiratory arrest, at doses between 15 and 40 mg/kg after intravenous (i.v.) administration.
- ATPA ((RS)-alfa-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionic acid) was dissolved in distilled water and test compound was dissolved in a polyoxyl 40 hydrogenated castor oil (5% Cremophor RHTM 40 (BASF)). Test compound was administered either i.v. 5, 30 or 120 min before or p.o.
- ED 50 value was calculated from at least three doses of test compound as the dose inhibiting 50% of the mice from having rigidity.
- the compound of example 1 and 2 exhibits an ED 50 of 0.1 mg/kg by i.v. administration in this test.
- compositions and unit dosages thereof may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
- Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing ten (10) milligrams of active ingredient or, more broadly, one (1) to one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
- the compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
- pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting vax, cocoa butter, and the like.
- the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
- a low melting vax such as a mixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions.
- parenteral injection liquid preparations can be formulated in solutions in aqueous polyethylene glycol solution.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
- viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the pharmaceutical preparations are preferably in unit dosage forms.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
- the compounds of this invention are extremely useful in the treatment of central nervous system disorders related to their biological activity.
- the compounds of this invention may accordingly be administered to a subject, including a human, in need of treatment, alleviation, or elimination of a disorder or disease associated with the biological activity of the compounds.
- excitatory amino acid dependent including glutamate and/or aspartate dependent, psychosis, excitatory amino acid dependent, including glutamate and/or aspartate dependent anoxia, excitatory amino acid dependent, including glutamate and/or aspartate dependent ischemia, excitatory amino acid dependent, including glutamate and/or aspartate dependent Parkinsonism, excitatory amino acid dependent, including glutamate and/or aspartate dependent, convulsions and excitatory amino acid dependent, including glutamate and/or aspartate dependent migraine.
- Suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
- the heat treated material was placed directly on top of a SiO 2 column, and flash chromatographed first with ethyl acetate as eluent, and then ethyl acetate/methanol (9:1) whereby the purple coloured product was eluted.
- the purple fractions were collected and evaporated to leave 2.3 g of the impure product as a brownish powder.
- a sample of the pure product was obtained after additional purification on SiO 2 with ethyl acetate/tetrahydrofurane (1:1) as eluent.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Luminescent Compositions (AREA)
- Conductive Materials (AREA)
Abstract
The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R21 and R22 each independently are alkyl; and
R1, R2, R3, R4, R11, R12, R13, and R14 each independently are hydrogen, halogen, CF3, CN, or NO2.
The compounds are useful as in vivo active glutamate antagonists.
Description
The present invention relates to novel excitatory amino acid antagonists, including glutamate antagonists, a method of treatment therewith, pharmaceutical compositions comprising the compounds and to a method of preparing the novel compounds of the invention.
It is an object of the present invention to provide novel excitatory amino acid antagonists, including glutamate and/or aspartate antagonists which are useful in the treatment of disorders or diseases of a living animal body, including a human, and especially in the treatment of disorders or diseases which are responsive to the antagonization of glutamate and/or aspartate of such a living animal body.
Another object of the present invention is to provide a method of treating disorders or diseases of a living animal body, including a human, responsive to the antagonization of glutamate and aspartate which comprises administering to a living animal body, including a human, in need thereof a compound of the invention.
A third object of the present invention is to provide novel pharmaceutical compositions for the treatment of disorders or diseases of a living animal body, including a human, responsive to the antagonization of glutamate and aspartate.
Other objects will become apparent to any skilled in the art hereinafter.
Excessive excitation by neurotransmitters can cause the degeneration and death of neurons. It is believed that this degeneration is in part mediated by the excitotoxic actions of the excitatory amino acids (EAA), glutamate and aspartate, at the N-methyl-D-aspartate (NMDA), the alfa-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor, the quisqualate receptor and the kainate receptor. This excitotoxic action is responsible for the loss of neurons in cerebrovascular disorders such as cerebral ischemia or cerebral infarction resulting from a range of conditions, such as thromboembolic or haemorrhagic stroke, cerebral vasospasm, hypoglycaemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery and cerebral trauma as well as lathyrism, Alzheimer's, and Huntington's diseases.
The compounds of the present invention may also be useful in the treatment of schizophrenia, Parkinsonism, epilepsy, anxiety, pain and drug addiction.
Most, if not all antagonists of the excitatory amino acids, including glutamate, as well as glutamate antagonists at the AMPA and/or kainate receptors have demonstrated limited, but still significant in vivo activity, for example as demonstrated by their ability to antagonize AMPA induced convulsions. Therefore there is a still unmet need for the identification of in vivo potent glutamate antagonists.
The invention then, inter alia, comprises the following, alone or in combination:
A compound having the formula ##STR2## or a pharmaceutically acceptable salt thereof wherein R21 and R22 each independently are alkyl; and
R1, R2, R3, R4, R11, R12, R13, and R14 each independently are hydrogen, halogen, CF3, CN, or NO2 ;
and a compound as above or a pharmaceutically acceptable salt thereof, wherein R21 and R22 are each methyl, R2, R4, R12, and R14 are each NO2, and R1, R3, R11 and R13 are each hydrogen;
and further a method of treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the antagonization of an excitatory amino acid, including glutamate and/or aspartate, which comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound as any above;
and a method as above wherein cerebrovascular disorders are treated;
and a method as above wherein Alzheimer's disease, Huntington's diseases, schizophrenia, Parkinsonism, epilepsy, anxiety, pain, drug addiction or the degenerative diseases or disorders following cerebral ischemia or cerebral infarction is treated;
and further a pharmaceutical composition comprising a therapeutically-effective amount of a compound as any above together with at least one pharmaceutically-acceptable carrier;
and further a method for the preparation of a compound as any above, characterized by
a) heating a compound having the formula: ##STR3## wherein R22, R1, R2, R3, and R4 each have the meanings set forth above, and wherein R is alkyl or benzyl;
b) reacting a compound having the formula ##STR4## wherein R22, R1, R2, R3, and R4 each have the meanings set forth above, with benzylamine.
Examples of pharmaceutically-acceptable addition salts include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate, oxalate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, salicylate and the acetate. Such salts are formed by procedures well known in the art.
Halogen is fluorine, chlorine, bromine, or iodine; chlorine and bromine are preferred groups.
Alkyl means a straight chained or branched chain of from one to six carbon atoms or cyclic alkyl of from three to seven carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; methyl, ethyl, propyl and isopropyl are preferred groups.
The compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
Some of the compounds of the present invention exist in (+) and (-) forms as well as in racemic forms. Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof, with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example. The compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the present invention with an optically active chloroformate or the like.
Additional methods for the resolvation of optical isomers, known to those skilled in the art may be used, and will be apparent to the average skilled in the art. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York
Starting materials for the processes described in the present application are known or can be prepared by known processes from commercially available chemicals. The products of the reactions described herein are isolated by conventional means such as extraction, crystallization, distillation, chromatography, and the like.
The compounds of the invention exhibit valuable biological properties because of their strong excitatory amino acid (EAA), including glutamate and/or aspartate antagonizing properties.
In vivo activity (ATPA-induced rigidity)
The selective glutamate receptor agonist at the AMPA(quisqualate)/glutamate receptor, ATPA, induce rigidity in female NMRI mice at doses between 3 and 15 mg/kg and clonic-tonic seizures and death, probably due to respiratory arrest, at doses between 15 and 40 mg/kg after intravenous (i.v.) administration. Method: ATPA ((RS)-alfa-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionic acid) was dissolved in distilled water and test compound was dissolved in a polyoxyl 40 hydrogenated castor oil (5% Cremophor RH™ 40 (BASF)). Test compound was administered either i.v. 5, 30 or 120 min before or p.o. 30 min before an i.v. administration of 15 mg/kg of ATPA to 8 female NMRI mice per dose and the number of mice experiencing rigidity 5 min later was noted. An ED50 value was calculated from at least three doses of test compound as the dose inhibiting 50% of the mice from having rigidity.
The compound of example 1 and 2 exhibits an ED50 of 0.1 mg/kg by i.v. administration in this test.
The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing ten (10) milligrams of active ingredient or, more broadly, one (1) to one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
The compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.
In, tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting vax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
For preparing suppositories, a low melting vax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated in solutions in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
The compounds of this invention are extremely useful in the treatment of central nervous system disorders related to their biological activity. The compounds of this invention may accordingly be administered to a subject, including a human, in need of treatment, alleviation, or elimination of a disorder or disease associated with the biological activity of the compounds. This includes especially excitatory amino acid dependent, including glutamate and/or aspartate dependent, psychosis, excitatory amino acid dependent, including glutamate and/or aspartate dependent anoxia, excitatory amino acid dependent, including glutamate and/or aspartate dependent ischemia, excitatory amino acid dependent, including glutamate and/or aspartate dependent Parkinsonism, excitatory amino acid dependent, including glutamate and/or aspartate dependent, convulsions and excitatory amino acid dependent, including glutamate and/or aspartate dependent migraine. Suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
The following nonlimiting examples illustrate the present invention further.
A solution of 5,7-dinitro-1-methyl-indole-2,3-dione-3-O-benzyle oxime (19 g) in ethylacetate (ethyl acetate, 150 ml) was charged with SiO2 (0.0016-0.040 mm, 90 g). The mixture was evaporated to dryness. The residue was then heated to 230° C. under vacum (100 mm Hg) for 90 min.
The heat treated material was placed directly on top of a SiO2 column, and flash chromatographed first with ethyl acetate as eluent, and then ethyl acetate/methanol (9:1) whereby the purple coloured product was eluted. The purple fractions were collected and evaporated to leave 2.3 g of the impure product as a brownish powder. A sample of the pure product was obtained after additional purification on SiO2 with ethyl acetate/tetrahydrofurane (1:1) as eluent.
Mp. >300° C.
1-H NMR (250 MHz, D-4-MEOH) :∂=3.4 ppm (S,3H), 8.1 ppm(S broad, 1H), 8.4 ppm (S,1H)
A mixture of 5,7-dinitro-1-methyl-indole-2,3-dione (2.5 g), benzyl amine (3.3 ml) and acetic acid (3.4 ml) was refluxed in abs. ethanol (50 ml) for 30 min. The mixture was then cooled to ambient temperature, and the precipitate was removed by filtration. This left 0.8 g of impure product as a dark solid, which was purified as described in Example 1.
Claims (7)
1. A compound having the formula ##STR7## or a pharmaceutically-acceptable salt thereof wherein R21 and R22 each independently are alkyl; and
R1, R2, R3, R4, R11, R12, R13, and R14, each independently are hydrogen, halogen, CF3, CN, or NO2, at least one of R1, R2, R3, R4, R11, R12, R13, and R14 being other than hydrogen.
2. A compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R21 and R22 are each methyl, R2, R4, R12, and R14 are each NO2, and R1, R3, R11 and R13 are each hydrogen.
3. A method of treating a disorder or disease of a living animal body, which disorder or disease is responsive to the antagonization of the excitatory amino acid glutamate, which comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound of claim 1.
4. The method of claim 3 wherein a cerebrovascular disorder is treated.
5. The method of claim 3 wherein Alzheimer's disease, Huntington's disease, schizophrenia, Parkinsonism, epilepsy, anxiety, pain, drug addiction or a degenerative disease or disorder following cerebral ischemia or cerebral infarction is treated.
6. A pharmaceutical composition comprising a therapeutically-effective amount of a compound of claim 1 together with at least one pharmaceutically-acceptable carrier.
7. A method of claim 3, wherein, in the compound employed, R21 and R22 are each methyl, R2, R4, R12, and R14 are each NO2, and R1, R3, R11, and R13, are each hydrogen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK93696A DK69693D0 (en) | 1993-06-14 | 1993-06-14 | THE COLOR PURPLE |
DK0696/93 | 1993-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
US5478859A true US5478859A (en) | 1995-12-26 |
Family
ID=8096489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/259,016 Expired - Fee Related US5478859A (en) | 1993-06-14 | 1994-06-13 | Indole-derivatives, method of treatment therewith, and pharmaceutical compositions comprising such compounds |
Country Status (5)
Country | Link |
---|---|
US (1) | US5478859A (en) |
EP (1) | EP0629615B1 (en) |
AT (1) | ATE189889T1 (en) |
DE (1) | DE69423055T2 (en) |
DK (2) | DK69693D0 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
US6413948B1 (en) | 1996-09-27 | 2002-07-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565580A (en) * | 1994-01-27 | 1996-10-15 | Neurosearch A/S | Glutamate Antagonists |
EP2140864A3 (en) * | 2001-01-31 | 2010-01-27 | H.Lundbeck A/S | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods |
US7642281B2 (en) | 2002-08-07 | 2010-01-05 | Helicon Therapeutics, Inc. | Indolone compounds useful to treat cognitive impairment |
CA2633829A1 (en) * | 2005-12-09 | 2007-06-21 | Helicon Therapeutics, Inc. | Indolone compounds useful to treat cognitive impairment |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE69677B1 (en) * | 1989-12-11 | 1996-10-02 | Neurosearch As | Isatine derivatives their preparation and use |
US5192792A (en) * | 1990-12-07 | 1993-03-09 | Warner-Lambert Company | Isatine derivatives, and their method of use |
US5164404A (en) * | 1991-03-15 | 1992-11-17 | Neurosearch A/S | Hydrazone derivatives and their use |
US5565580A (en) * | 1994-01-27 | 1996-10-15 | Neurosearch A/S | Glutamate Antagonists |
-
1993
- 1993-06-14 DK DK93696A patent/DK69693D0/en not_active Application Discontinuation
-
1994
- 1994-06-01 EP EP94610030A patent/EP0629615B1/en not_active Expired - Lifetime
- 1994-06-01 AT AT94610030T patent/ATE189889T1/en not_active IP Right Cessation
- 1994-06-01 DE DE69423055T patent/DE69423055T2/en not_active Expired - Fee Related
- 1994-06-01 DK DK94610030T patent/DK0629615T3/en active
- 1994-06-13 US US08/259,016 patent/US5478859A/en not_active Expired - Fee Related
Non-Patent Citations (9)
Title |
---|
Cerebrovasc. Brain metab. Rev., vol. 6, No. 3, pp. 225 256 (1994). * |
Cerebrovasc. Brain metab. Rev., vol. 6, No. 3, pp. 225-256 (1994). |
Chemical Abstracts, vol. 67, abstract 118105z, 1967. * |
NeuroReport, vol. 5, No. 8, pp. 877 880 (1994). * |
NeuroReport, vol. 5, No. 8, pp. 877-880 (1994). |
New Eng. J. Med., vol. 330, No. 9, pp. 613 622 (1994). * |
New Eng. J. Med., vol. 330, No. 9, pp. 613-622 (1994). |
Therapeutic opportunities in modulators of excitatory amino acid mediated neurotransmission, In: P. Krogsgaard Larsen, J.J. Hansen, eds Excitatory Amino Acid Receptors, Design of Agonists and Antagonists, Ellis Horwood, 1993, pp. 352 375. * |
Therapeutic opportunities in modulators of excitatory amino acid-mediated neurotransmission, In: P. Krogsgaard-Larsen, J.J. Hansen, eds Excitatory Amino Acid Receptors, Design of Agonists and Antagonists, Ellis Horwood, 1993, pp. 352-375. |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
US5985855A (en) * | 1996-09-27 | 1999-11-16 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using NAALADase inhibitors |
US6004946A (en) * | 1996-09-27 | 1999-12-21 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
US6413948B1 (en) | 1996-09-27 | 2002-07-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
DK69693D0 (en) | 1993-06-14 |
EP0629615B1 (en) | 2000-02-23 |
ATE189889T1 (en) | 2000-03-15 |
EP0629615A1 (en) | 1994-12-21 |
DK0629615T3 (en) | 2000-07-03 |
DE69423055T2 (en) | 2000-08-03 |
DE69423055D1 (en) | 2000-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69205327T2 (en) | Urea derivatives, processes for their preparation and medicines containing them. | |
RU2079493C1 (en) | Method of synthesis of 4-amino-2-(4-methylpiperazine-1-yl)-5-(2,3,5-trichlorophenyl)- -pyrimidine or its acid additive salt | |
US4837224A (en) | (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide compositions | |
LU88248A1 (en) | INDOLE DERIVATIVES | |
EP1202969A2 (en) | Biphenyl derivatives, production thereof and use as medicines | |
DE69714265T2 (en) | TETRAHYDROCHINOLIN DERIVATIVES AS EAA ANTAGONISTS | |
DE69132167T2 (en) | CONDENSED BENZOXA RING CONNECTION, THEIR PRODUCTION AND THIS MEDICINAL PRODUCT | |
DE69608551T2 (en) | BICYCLIC AMINE DERIVATIVES AND THEIR USE AS ANTIPSYCHOTIC ACTIVE SUBSTANCES | |
EP0698025B1 (en) | Ampa antagonists and a method of treatment therewith | |
US5478859A (en) | Indole-derivatives, method of treatment therewith, and pharmaceutical compositions comprising such compounds | |
US5565580A (en) | Glutamate Antagonists | |
SK93198A3 (en) | Quinoline-2-(1h)-one derivative, preparation method thereof and pharmaceutical composition containing the same | |
DE60015732T2 (en) | AMID COMPOUNDS FOR STRENGTHENING THE CHOLINERGIC EFFECT | |
DE69514533T2 (en) | CONDENSED INDOLES AND CHINOXALINE DERIVATIVES, THEIR PRODUCTION AND USE AS GLUTAMATE ANTAGONISTS | |
DE69514532T2 (en) | INDOL-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PRODUCTION AND USE | |
EP0548664B1 (en) | 2,3,3a-5,9b-hexahydro-1H-benzo(e)indole derivatives | |
KR102677119B1 (en) | Novel cannabidiol derivative, process for preparing the same and composition for improving cognitive function comprising the same | |
US5843945A (en) | AMPA antagonists and a method of treatment | |
EP0633262B1 (en) | Novel isatineoxime derivatives, their preparation and use | |
RU2114839C1 (en) | 2,3,4,5-tetrahydro-1h-3-benzazepines, pharmaceutical composition, method of treatment and methods of synthesis | |
JP3270524B2 (en) | Novel isatin oxime derivatives, their production and use | |
US5223527A (en) | Isatineoxime derivatives and their use | |
EP0001585B1 (en) | Piperazino-pyrrolobenzodiazepines, methods for their preparation and pharmaceutical compositions containing them | |
US6541502B1 (en) | 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity | |
US6541501B2 (en) | 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NEUROSEARCH A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WATJEN, FRANK;DREJER, JORGEN;JENSEN, LEIF HELTH;REEL/FRAME:007089/0184 Effective date: 19940531 |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20031226 |